Non-aspirin NSAIDs and head and neck cancer mortality in a Danish nationwide cohort study

Cour, Cecilie Dovey de la; Dehlendorff, Christian; Buchwald, Christian von; Garset‐Zamani, Martin; Grønhøj, Christian; Carlander, Amanda-Louise Fenger; Friis, Søren; Kjær, Susanne K.

doi:10.1016/j.canep.2022.102121

Cancer Epidemiology

2022

DOI: 10.1016/j.canep.2022.102121

|View full text |Cite

Non-aspirin NSAIDs and head and neck cancer mortality in a Danish nationwide cohort study

Cecilie Dovey de la Cour

Christian Dehlendorff

Christian von Buchwald

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Drug Repositioning for Treatment of Head and Neck Cancers

Kwon

2023

Korean J Otorhinolaryngol-Head Neck Surg

View full text Add to dashboard Cite

Head and neck cancer (HNC) is a complex disease that poses significant therapeutic challenges. Traditional treatment options such as surgery, radiation, and chemotherapy have limited efficacy and often result in significant side effects. In recent years, drug repositioning has emerged as a promising strategy to identify new therapeutic options for HNC. Drug repositioning involves repurposing existing drugs, already approved for other indications, for the treatment of HNC. This approach takes advantage of existing knowledge about drug safety and efficacy, reducing the time and cost needed to develop new drugs. By leveraging the known safety profiles, pharmacokinetic, and pharmacodynamic properties of these drugs, drug repositioning can accelerate the drug development process and reduce costs. In this review, the current status of drug repositioning efforts for HNC and the challenges and opportunities associated with this approach are discussed. We also highlight some of the most promising drug candidates that have emerged from recent studies and clinical trials. Overall, drug repositioning has the potential to significantly improve the treatment landscape for HNC and offer new hope for patients with this challenging disease.

show abstract

Drug Repositioning for Treatment of Head and Neck Cancers

Kwon

2023

Korean J Otorhinolaryngol-Head Neck Surg

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Non-aspirin NSAIDs and head and neck cancer mortality in a Danish nationwide cohort study

Cited by 1 publication

References 40 publications

Drug Repositioning for Treatment of Head and Neck Cancers

Drug Repositioning for Treatment of Head and Neck Cancers

Contact Info

Product

Resources

About